Each year, Baylor College of Medicine faculty are recognized for their outstanding published scientific contributions to clinical and basic science research over the past three years through the Michael E. DeBakey M.D. Award for Excellence in Research.
This years 2022 recipients are Dr. Peter Hotez and Dr. Maria Elena Bottazzi (joint awardees), Dr. Joseph Hyser, Dr. Katherine King, Dr. Irina Larina, Dr. Scott A. LeMaire and Dr. Ying Shen (joint awardees) and Dr. Sundeep Keswani.
Each year we celebrate and honor researchers from our Baylor community who have made significant contributions to improving healthcare, said Dr. Paul Klotman, Baylor president, CEO and executive dean. These awards celebrate the legacy of innovation in research and medicine set forth by Dr. DeBakey.
The awards, named in honor of pioneering heart surgeon Dr. Michael E. DeBakey, the first president of Baylor College of Medicine, and sponsored by the DeBakey Medical Foundation, include a commemorative medallion and funds to support further research.
The eight researchers were recognized and presented their work at a small in-person ceremony on Wednesday, Aug. 17.
It is an honor to recognize this group. They represent the continued work here at Baylor to improve health and humanity and each researcher demonstrates the impact to science and the community, said Dr. Mary Dickinson, senior vice president and dean of research at Baylor.
Dr. Maria Elena BottazziAssociate dean of the National School for Tropical Medicine at Baylor College of Medicine and co-director of the Texas Children's Hospital Center for Vaccine Development
Dr. Bottazzi is an internationally recognized tropical and emerging disease vaccinologist, global health advocate and co-creator of a patent-free, open science COVID-19 vaccine technology that led to the development of Corbevax, a COVID-19 vaccine for the world. She pioneers and leads the advancement of a robust infectious and tropical disease vaccine portfolio tackling diseases such as coronavirus, hookworm, schistosomiasis and Chagas that disproportionally affect the worlds poorest populations. She also has established innovative partnerships in Latin America, the Middle East and Southeast Asia, making significant contributions to innovative educational and research programs, catalyzing policies and disseminating science information to reach a diverse set of audiences.
As global thought-leader she has received national and international highly regarded awards, has more than 280 scientific papers and participated in more than 250 conferences worldwide. She is a member of the National Academy of Science of Honduras and an Emerging Leader in Health and Medicine of the National Academy of Medicine in the U.S.
Bottazzi is a fellow of the American Society of Tropical Medicine and Hygiene (ASTMH), the Executive Leadership in Academic Medicine (ELAM) and the Leshner Leadership Institute for Public Engagement and senior fellow of the American Leadership Forum (ALF). Forbes LATAM in 2020 and 2021 selected Bottazzi as one of 100 Most Powerful Women in Central America. Bottazzi has served in several national academies ad-hoc committees and serves as co-chair of the Vaccines and Therapeutics Taskforce of the Lancet Commission on COVID-19. In 2022, alongside Dr. Peter Hotez, she was nominated by Congresswoman Lizzie Fletcher of Texas for the Nobel Peace Prize.
Dr. Peter HotezDean of the National School of Tropical Medicine at Baylor College of Medicine and co-director of the Texas Childrens Hospital Center for Vaccine Development
Dr. Hotez is an internationally recognized physician-scientist in neglected tropical diseases and vaccine development. As co-director of the Texas Childrens Center for Vaccine Development, he leads a team and product development partnership for developing new vaccines for hookworm infection, schistosomiasis, leishmaniasis, Chagas disease and SARS/MERS/SARS-2 coronavirus, diseases affecting hundreds of millions of children and adults worldwide, while championing access to vaccines globally and in the U.S.
In December 2021, Hotez led efforts at the Texas Childrens Center for Vaccine Development to develop a low-cost recombinant protein COVID vaccine for global health, resulting in emergency use authorization in India. In 2022 Hotez and his colleague Dr. Maria Elena Bottazzi were nominated for the Nobel Peace Prize for their work to develop and distribute a low-cost COVID-19 vaccine to people of the world without patent limitation.
In 2014-16, he served in the Obama Administration as U.S. Envoy, focusing on vaccine diplomacy initiatives between the U.S. government and countries in the Middle East and North Africa. In 2018, he was appointed by the U.S. State Department to serve on the Board of Governors for the U.S.-Israel Binational Science Foundation, and he is frequently called on frequently to testify before U.S. Congress. He has served on infectious disease task forces for two consecutive Texas governors. For these efforts in 2017 he was named by FORTUNE Magazine as one of the 34 most influential people in healthcare, while in 2018 he received the Sustained Leadership Award from Research!America.
Most recently as both a vaccine scientist and autism parent, he has led national efforts to defend vaccines and to serve as an ardent champion of vaccines going up against a growing national antivax threat. In 2019, he received the Award for Leadership in Advocacy for Vaccines from the American Society of Tropical Medicine and Hygiene. In 2021 he was recognized by scientific leadership awards from the Association of American Medical Colleges and the American Medical Association, in addition to being recognized by the Anti-Defamation League with its annual Popkin Award for combating antisemitism.
Dr. Joseph HyserAssistant professor of molecular virology and microbiology and member of the Alkek Center for Metagenomics and Microbiome Research
Dr. Joseph Hysers research work is dedicated to improving our understanding of host-pathogen interactions. He has focused on characterizing host signaling pathways that enteric viruses, such as rotavirus, destabilize to cause gastrointestinal disease. His work stands out because it is shifting prevailing paradigms within the field.
In recent work, Hyser used calcium biosensor cell lines and organoids he developed to perform long-term live calcium imaging throughout rotavirus infections. This work is paradigm shifting because it firmly established that rotavirus increase calcium through hundreds of discrete calcium signaling events rather than a general, monophasic increase in cytosolic calcium levels. This study also led to the discovery of multiple distinct types of calcium signals present at different stages of the infection.Another study showed that calcium-conducting viroporins are a broadly conserved strategy used by viruses to exploit host calcium signaling pathways. This finding has opened the door to identify commonly exploited host pathways for which host-targeted antiviral drugs could be developed.
Recently, Hyser published the first direct evidence that viruses can trigger aberrant calcium signaling in uninfected cells by exploiting a host paracrine signaling pathway. Live imaging data show calcium signals coming from rotavirus-infected cells and spreading to surrounding uninfected cellsa type of signal called intercellular calcium waves. He found that eliminating the calcium waves severely reduced rotavirus replication, suggesting that rotavirus has evolved to co-opt this host intercellular signal to increase its replication. Taken together, Hysers work establishes a new mechanism by which viruses commandeer nearby uninfected cells to contribute to pathogenesis through paracrine signaling.
Dr. Katherine KingAssociate professor of pediatrics infectious diseases and member of the Dan L Duncan Comprehensive Cancer Center and Center for Cell and Gene Therapy
Dr. Kings research focuses on the effects of infection and inflammation on primitive hematopoiesis. As a pediatric infectious diseases physician at Texas Childrens Hospital, King recognized the need to understand bone marrow suppressive effects of chronic infection, and she led the field to characterize hematopoietic stem cell responses in the context of animal models of infection. Her review on the topic of inflammatory modulation of hematopoietic stem cells altered the way the field views the interactions between systemic inflammation and stem cells, with continuing repercussions in the fields of malignant and nonmalignant hematology, aging and immunology.
Using a multidisciplinary approach, she has pioneered the concept that hematopoietic stem cells are extremely sensitive to inflammatory signals in the bone marrow environment. Her research has defined a role for inflammatory signaling in bone marrow suppression following chronic infection and in the emergence of clonal hematopoiesis, a recently defined phenomenon that drives cancer risk and cardiovascular disease in advanced age.
Over the past three years, her research efforts have resulted in 9 senior-author research articles in leading journals in her field including Cell Stem Cell, Cell Reports, and eLife. Kings highly innovative and impactful work at the intersection of immunology and hematology has made her an international leader in the field of stem cell biology. She is a skilled clinician, a healthcare advocate, scientist, administrative leader and trusted mentor.
Dr. Irina LarinaAssociate professor of integrative physiology
Dr. Irina Larinas lab is dedicated to the development of new biophotonic technologies to define pathways involved in live embryo progression and, specifically, cardiac development. She also applies her new biophotonic methods to image developmental processes in various mouse models to elucidate pathophysiological mechanisms underlying reproductive disorders. Larina also develops data processing methods that enable her to uncover new information about congenital defects and reproductive disorders that reveal the dynamics of developmental processes, which have not been accessible before.
Most recently she used second harmonic generation microscopy to image collage fibers in embryonic hearts, revealing a link between structural collagen and regional contractility that suggested a regulatory role for cardiomyocyte contractility in establishing mechanical homeostasis in the developing heart. These findings revealed new features of the biochemical alterations found in congenital heart defects and heart failure. In addition, her lab recently established a method to study the interactions between genetic and mechanical factors in both normal and pathogenic cardiogenesis in vivo, such as arrhythmias.
In the area of reproduction, Larinas innovative biophotonics technology provided direct visualization of the movement of oocytes and embryos in the fallopian tube. Identifying abnormalities in this process is critical for defining defects in mammalian fertilization and embryogenesis. Using her new approach, which combines optical coherence tomography with intravital imaging, Larina showed that cilia do not drive directional oocyte/embryo transport. The timing of the oocyte/embryo transport is primarily regulated by smooth muscle dynamics at different locations within the oviduct.
Dr. Scott A. LeMaireJimmy and Roberta Howell Professor of Cardiovascular Surgery, vice chair for research in the Michael E. DeBakey Department of Surgery, director of research in the Division of Cardiothoracic Surgery and professor of molecular physiology and biophysics
Dr. LeMaires primary clinical interest focuses on the management of patients with thoracic aortic disease, with a particular emphasis on treatment of aortic dissection and thoracoabdominal aortic aneurysms. His corresponding research program focuses on organ protection during aortic surgery, genetic aspects of thoracic aortic disease and molecular mechanisms of aortic degeneration.
He has received funding from the National Institutes of Health, the American Heart Association, the Thoracic Surgery Foundation and the Marfan Foundation for his research studying the pathobiology of thoracic aortic aneurysms and aortic dissection. LeMaire is a past-president of the Association for Academic Surgery and is the current editor-in-chief of the Journal of Surgical Research.
LeMaire also serves as a physician associate in the Department of Cardiovascular Surgery at the Texas Heart Institute and Baylor St. Lukes Medical Center.
Dr. Ying ShenProfessor of surgery and director of the Aortic Disease Research Laboratory
Dr. Shens research focuses on understanding the development of vascular diseases. She became the director of the Aortic Disease Research Laboratory in 2008, and has since focused on aortic aneurysms and dissections, highly lethal but poorly understood diseases. She has worked closely with collaborator Dr. Scott LeMaire and together, they have built a translational research program and developed several research directions to investigate the mechanisms of aortic injury, repair and remodeling. The ultimate goal of her research is to develop pharmacological treatments to prevent progressive aortic destruction, maladaptive remodeling and disease deterioration.
Dr. Sundeep KeswaniProfessor of surgery, pediatrics and obstetrics and gynecology, division chief of pediatric surgery and surgical director of basic science research at Texas Childrens Hospital
Dr. Sundeep Keswanis lab, the Laboratory for Regenerative Tissue Repair, is focused on understanding the molecular mechanism that underlies the fetus ability to regeneratively heal cutaneous wounds, as well as the development of novel therapies to achieve scarless wound healing in postnatal tissues, specifically the interaction of inflammation and extracellular matrix to drive fibrotic responses within human skin in response to injury. Most recently he has shown that bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection and that Interleukin-10 producing T lymphocytes (TR1 cells) reduce dermal scarring. In addition to his work in skin, his group also has discovered that hyaluronan attenuates tubulointerstitial scarring in kidney injury.During the last three years, he has published his research outcomes in highly prestigious journals such as Science, Annals of Surgery and JCI Insight.
Keswani also serves as a governor of the American College of Surgeons and continually publishes articles that examine the state of research and surgery, keeping surgeon-scientists highly relevant nationally.
The rest is here:
Baylor College of Medicine recognizes research excellence with DeBakey Awards - Baylor College of Medicine News
- Molecular discovery has potential to solve the billion-dollar global cost of poorly managed wound healing - Medical Xpress - March 29th, 2024
- Science Saturday: A year of new directions and advancements for ... - March 29th, 2024
- Diverse ways regenerative medicine is advancing health care - March 29th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 29th, 2024
- Global Organoids and Spheroids Market Set for Remarkable Growth, Reaching USD 7.70 Billion by 2034 with a CAGR ... - GlobeNewswire - March 29th, 2024
- Growth Projections for the Regenerative Medicine Market - BioProcess Insider - March 10th, 2024
- Regenerative Medicine - Cell Therapies - BioProcess Insider - March 10th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 10th, 2024
- Stem cell-based regenerative medicine - PMC - National Center for ... - February 27th, 2024
- Unlocking the Mysteries of the Hippo Pathway: A Leap Towards Conquering Cancer and Regenerating Tissues - Medriva - February 27th, 2024
- PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market - Yahoo Finance - February 27th, 2024
- Therapeutic Solutions International Files Patent on "Facilitating Effects" of JadiCells on Gene Therapy Mediated Cell ... - Yahoo Finance - February 27th, 2024
- RION Expands Manufacturing Operations with Cutting-Edge Facility in Rochester, Minnesota - Yahoo Finance - February 27th, 2024
- Hands-On Solutions: Applying Prosthetic Sensory Technology In Rehabilitation - Forbes - February 27th, 2024
- UC Irvine Embarks on a Transformative Journey in Stem Cell Research with a $4 Million Boost - BNN Breaking - February 27th, 2024
- Less Surgery, More Recovery: Here is How Regenerative Medicine is Shaping the Future for Neurosurgeons - News Channel Nebraska - February 27th, 2024
- SPONSORED: Regen Rx Offers Both Non-Invasive Regenerative Medicine Procedures and Ultrasound-Guided ... - exploreClarion.com - February 27th, 2024
- ROSM Celebrates 10 Years of Advancing Patient Care Through Regenerative Medicine - goskagit.com - February 27th, 2024
- Expanding the Horizons of Cell and Gene Therapy - RegMedNet - February 27th, 2024
- Regenerative medicine | NIST - February 10th, 2024
- Home - Kansas Regenerative Medicine - February 10th, 2024
- Translational Regenerative Medicine market is estimated to grow at a CAGR of 24.3% by 2034: Visiongain - Yahoo Finance - February 10th, 2024
- Cellular senescence is associated with osteonecrosis of the femoral head while mesenchymal stem cell conditioned ... - Nature.com - February 10th, 2024
- Top 3 grants in regenerative medicine: January 2024 - RegMedNet - February 10th, 2024
- Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024 - Yahoo Finance - February 10th, 2024
- Unlocking the power of stem cell therapy - Drug Target Review - February 10th, 2024
- Innovative stem cell therapy could be "game changer" in epilepsy - The Pharma Letter - February 10th, 2024
- Neurona lands $120m to advance regenerative cell therapy pipeline - Longevity.Technology - February 10th, 2024
- Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates ... - GlobeNewswire - February 10th, 2024
- Treating Joint Problems in the Modern Age: How Regenerative Medicine Paves the Way - Health shots - February 10th, 2024
- Cancer-related mutations appear in stem cell derivatives used in regenerative medicine, shows study - Phys.org - January 17th, 2024
- Researchers genetically modify stem cells to evade immunological rejection - University of Arizona - January 17th, 2024
- The Impact and Implications of Regenerative Medicine in Urology - Cureus - January 17th, 2024
- LVHN announces opening of new stem cell transplant center. Here's what that means for the Lehigh Valley - The Morning Call - January 17th, 2024
- Clinical applications of stem cell-derived exosomes | Signal Transduction and Targeted Therapy - Nature.com - January 17th, 2024
- Therapeutic Solutions International Launches Adult Stem Cell Therapy Company Focused on Curing Epilepsy - Business Wire - January 17th, 2024
- Cell Therapy Technologies Market Projected to Reach Valuation of USD 47.3 Billion at 24.7% CAGR from 2024-2033 ... - GlobeNewswire - January 17th, 2024
- Cancer Mutations in 22% of Stem Cells: Concern for Regenerative Medicine - BNN Breaking - January 17th, 2024
- San Jose blood stem cell donor meets 15-year-old whose life he saved in Los Angeles - The Mercury News - May 17th, 2023
- Regenerative medicine: Current therapies and future directions - April 23rd, 2023
- What Is Regenerative Medicine? | Goals and Applications | ISCRM - April 23rd, 2023
- Important Patient and Consumer Information About Regenerative Medicine ... - April 23rd, 2023
- Regenerative medicine can be a boon for those with Drug-Resistant Tuberculosis - Hindustan Times - April 23rd, 2023
- About Regenerative Medicine - Center for Regenerative ... - Mayo Clinic - April 7th, 2023
- Regenerative Medicine | National Institutes of Health (NIH) - April 7th, 2023
- Porcine Vaccine Market is estimated to be US$ 4.41 billion by 2030 with a CAGR of 7.50%during the forecast - EIN News - April 7th, 2023
- Advancing Safe and Effective Regenerative Medicine Products - March 21st, 2023
- Active Wound Care Market Rising demand for Skin Substitutes to boost the industry (2023-2033) | CAGR of 5.5% - EIN News - March 21st, 2023
- Veterinary Orthopedic Implants Market is estimated to be 421.3 Million by 2029 with a CAGR of 5.3% - By PMI - EIN News - March 21st, 2023
- ASKA Pharmaceutical : February 7 2023 EME and ASKA Announce Collaboration Agreement on Creating Novel PharmaLogical VHH to address an unmet medical... - February 8th, 2023
- A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field - Yahoo Finance - October 15th, 2022
- The Switch to Regenerative Medicine - Dermatology Times - October 15th, 2022
- The Alliance for Regenerative Medicine Announces Election of 2023 Officers, Executive Committee, and Board of Directors - GlobeNewswire - October 15th, 2022
- Mathematical model could bring us closer to effective stem cell therapies - Michigan Medicine - October 15th, 2022
- 'We have to find a way': FDA seeks solutions to aid bespoke gene therapy - BioPharma Dive - October 15th, 2022
- American Academy of Stem Cell Physicians to Offer Licensed Physicians Board Examination in Regenerative Medicine - GlobeNewswire - October 15th, 2022
- Discover Medical Advances in Cellular Therapy Research Using Cord Blood for Cancer, HIV, Cerebral Palsy and Autism During World Cord Blood Day 2022 -... - October 15th, 2022
- The Risk-Reward Proposition for CGT Clinical Trials - Applied Clinical Trials Online - October 15th, 2022
- Cell therapy weekly: Ray Therapeutics and Forge Biologics expand partnership - RegMedNet - October 15th, 2022
- FDA Expands Oversight of Cell and Gene Therapies - Pharmaceutical Technology Magazine - October 15th, 2022
- Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss - Business Wire - October 15th, 2022
- The Health Benefits Of Sea Moss, According To Experts - Forbes - October 15th, 2022
- ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of ... - The Bakersfield Californian - October 15th, 2022
- Pain Management & Regenerative Medicine Specialists DFW - September 4th, 2022
- Tissue Engineering and Regenerative Medicine - National Institute of ... - September 4th, 2022
- First U.S. patient receives autologous stem cell therapy to treat dry AMD - National Institutes of Health (.gov) - September 4th, 2022
- International Stem Cell and Regenerative Medicine Research and Therapeutic Center in Egypt - Construction Review - September 4th, 2022
- Regenerative Medicine Market to Garner Bursting Revenues [+USD 27.29 Billion] with Top Growing Companies During 2022-2029 - eTurboNews | eTN - September 4th, 2022
- Immusoft Takes First-Ever Engineered B Cell Therapy into Clinic - BioSpace - September 4th, 2022
- Addressing Diversity Barriers to Regenerative Medicine Free Press of Jacksonville - Jacksonville Free Press - September 4th, 2022
- TikoMed's ILB mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all... - September 4th, 2022
- Frequency Therapeutics to Participate in September Investor and Medical Conferences - Business Wire - September 4th, 2022
- Can the immortal jellyfish teach us how to reverse aging? - Earth.com - September 4th, 2022
- Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy - Business Wire - September 4th, 2022
- Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors - PR Newswire - September 4th, 2022
- Rise In Number Of CROS In Various Regions Such As Europe Is Expected To Fuel The Growth Of Induced Pluripotent Stem Cell Market At An Impressive CAGR... - September 4th, 2022
- Regenerative Medicine Partnering 2015 to 2022: Terms and Agreements Entered Into by the Leading Companies Worldwide - ResearchAndMarkets.com -... - August 19th, 2022
- Pain Relief Treatments: The Benefits of Regenerative Medicine From Head to Toe - 30Seconds.com - August 19th, 2022
- FDA Issues Draft Guidance to Facilitate Development of Human Gene Therapy, CAR T Cell, and Regenerative Medicine Products - Wilson Sonsini Goodrich... - August 19th, 2022
- Marco Quarta to present at the 9th Aging Research & Drug Discovery Meeting 2022 - EurekAlert - August 19th, 2022